Form4insider filings, from the source

SEC Form 4 · accession 0001676170-26-000022

Maze Therapeutics, Inc. · MAZE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jason V Coloma
Officer — Chief Executive Officer · Director
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 4:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001842295

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2Sep 2, 2026S9,852$26.376D40,148D
Common StockF3Sep 2, 2026S1,375$27.1211D38,773D
Common StockF4Sep 3, 2026S11,282$26.0133D27,491D
Common StockSep 3, 2026S129$25.7749D27,362D
Common StockF5holding———18,151IThe Coloma 2021 Irrevocable Trust
Common StockF6holding———223,355IColoma Family Trust

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses